Holly Lofton and Jennifer Manne-Goehler say safety looks similar to other GLP-1s so far, and Lofton reports gray market patients who saw no weight loss at all.
Recap by typeshit. Full story at Women's Health.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Lilly is moving against sellers of copycat versions of its unapproved triple agonist, the latest step in the push against gray market retatrutide.
In a four month trial of 39 adults, both groups regained about 3.6% of body weight versus 10.75% with usual care. Researchers say larger, longer studies are needed.
Loading…